Lisocabtagene maraleucel
http://dbpedia.org/resource/Lisocabtagene_maraleucel an entity of type: Thing
Лисокабтаген маралеусел — лекарственный препарат для генной терапии B-крупноклеточной лимфомы. Одобрен для применения: США (2021)
rdf:langString
Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma. Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness.
rdf:langString
rdf:langString
Lisocabtagene maraleucel
rdf:langString
Lisocabtagene maraleucel
xsd:integer
57641853
xsd:integer
1112989893
rdf:langString
None
xsd:integer
4297236
rdf:langString
DB16582
rdf:langString
D11990
rdf:langString
Rx-only
rdf:langString
JCAR017, LM
rdf:langString
Breyanzi
xsd:integer
7
rdf:langString
Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma. Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness. Lisocabtagene maraleucel, a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, is the third gene therapy approved by the U.S. Food and Drug Administration (FDA) for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Lisocabtagene maraleucel was approved for medical use in the United States in February 2021.
rdf:langString
Лисокабтаген маралеусел — лекарственный препарат для генной терапии B-крупноклеточной лимфомы. Одобрен для применения: США (2021)
rdf:langString
Lisocabtagene_maraleucel
rdf:langString
Rx-only
rdf:langString
/Schedule D
rdf:langString
Rx-only
xsd:nonNegativeInteger
15113
rdf:langString
Breyanzi
xsd:string
4297236
xsd:string
DB16582
xsd:string
7K2YOJ14X0
xsd:string
D11990